CN111377920B - Method for refining quinine compound containing quaternary ammonium group - Google Patents
Method for refining quinine compound containing quaternary ammonium group Download PDFInfo
- Publication number
- CN111377920B CN111377920B CN201811615105.2A CN201811615105A CN111377920B CN 111377920 B CN111377920 B CN 111377920B CN 201811615105 A CN201811615105 A CN 201811615105A CN 111377920 B CN111377920 B CN 111377920B
- Authority
- CN
- China
- Prior art keywords
- organic solvent
- solution
- crude
- compound
- quaternary ammonium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
The present invention relates to a composition containing quaternary phosphonium represented by the following formula (1)A refining method of an ammonium group quinine compound comprises the steps of mixing a crude compound with an organic solvent-water mixed solution, heating to dissolve the crude compound until the solution is clear, filtering while the solution is hot, and cooling and crystallizing the filtrate. Researches find that the quinine compound containing quaternary ammonium groups is refined by taking the mixed solution of water and an organic solvent as a crystallization solvent, most impurities such as reaction byproducts, inorganic salts, unreacted raw materials and the like can be effectively removed through a recrystallization process, the use of the organic solvent is obviously reduced, the pollution to the environment is avoided or reduced, the product purity is obviously improved, and the obtained product meets the standards of medicinal raw material medicines.
Description
Technical Field
The invention belongs to the technical field of chemical drugs, and particularly relates to a refining method of a quinine compound containing quaternary ammonium groups.
Background
Pharmacological research shows that quinine compounds containing quaternary ammonium groups shown in the following formula (1) have the activity of blocking cholinergic receptors; the compound has obvious inhibition effect on guinea pig specific allergic asthma. More importantly, the compound cannot penetrate through the blood brain barrier and can not enter the central nervous system, and no central psychomimetic side effect exists; the compound can be used for treating bronchial asthma, chronic obstructive pulmonary disease, common cold, rhinitis, peptic ulcer, dysentery, arrhythmia, etc.
The prior method for preparing quinine compounds containing quaternary ammonium groups as shown in the following formula (1) mainly uses phenyl-R1Ethylene oxide, quinine alcohol, alkyl halides R2X is a raw material, and a quaternary ammonium salt structure is formed in a final product. The existing refining method mainly uses acetone as a solvent to recrystallize a crude product of the acetone. However, it has been found that acetone has a poor purification effect on the above-mentioned compounds and it is difficult to remove impurities such as inorganic salts. In addition, the existing process refining method needs to recrystallize the crude product for many times, thus greatly improving the refining efficiencyThe cost of the product is greatly increased and the work-up of the solvent is increased. The defects of economy, environmental protection and the like are inevitable in the industrial implementation of the method.
In view of the above, the present invention is particularly proposed.
Disclosure of Invention
In order to solve the technical problems, the invention provides an economic, environment-friendly and efficient method for refining quinine compounds containing quaternary ammonium groups, which can effectively remove impurities such as reaction byproducts, inorganic salts and the like, can prepare high-purity products, and can also effectively improve the color of the products.
The research of the invention finds that the mixed solution of the organic solvent and water is used as the crystallization solvent to refine the quinine compound containing the quaternary ammonium group, most impurities such as reaction byproducts, inorganic salts, unreacted raw materials and the like can be effectively removed through one-time recrystallization process, the use of the organic solvent is obviously reduced, the pollution to the environment is avoided or reduced, the product purity is obviously improved, and the obtained product meets the standards of medicinal raw material medicines.
Specifically, the invention provides a method for refining a quinine compound containing a quaternary ammonium group, which is shown in the following formula (1), and the method is characterized in that an organic solvent-water mixed solution is used for recrystallizing a crude compound. Mixing the crude compound with an organic solvent-water mixed solution, heating to dissolve the crude compound until the solution is clear, filtering while the solution is hot, and cooling and crystallizing the filtrate to obtain the high-purity quinine compound containing the quaternary ammonium group. The organic solvent is isopropanol or ethanol.
In the formula (1), the reaction mixture is,
R1、R2each independently selected from alkyl;
R3is phenyl; or R3Is phenyl, optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from alkyl;
x is independently selected from halogen, organic or inorganic acid radical.
Further, the alkyl group means a straight-chain alkyl group, a branched-chain alkyl group or a cyclic alkyl group having 1 to 12 carbon atoms, and specifically includes, for example, a methyl group, an ethyl group, a propyl group, an isopropyl group, a n-butyl group, an isobutyl group, a tert-butyl group, a cyclopropyl group, a cyclopentyl group, a cyclohexyl group and the like. Preferably a straight-chain, branched-chain or cyclic alkyl group having 1 to 8 carbon atoms, more preferably a straight-chain, branched-chain or cyclic alkyl group having 3 to 6 carbon atoms.
Further, R1Independently selected from cyclopropyl, cyclopentyl or cyclohexyl.
Further, R2Independently selected from methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl or tert-butyl.
Further, R3Is phenyl; or R3Is phenyl, optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from methyl, ethyl, propyl or isopropyl.
Further, X is independently selected from fluorine, chlorine, bromine, iodine, methane sulfonate, p-toluene sulfonate or other acid groups which can be used as medicine.
Further, R1Is cyclopropyl, cyclopentyl or cyclohexyl; r2Is methyl; r3Is phenyl; x is fluorine, chlorine, bromine or iodine.
Furthermore, the quinine compound configuration containing the quaternary ammonium group shown in the formula (1) is a diastereoisomer or a pure optical isomer.
The quinine compound containing the quaternary ammonium group shown in the formula (1) can be prepared by adopting a conventional method in the field, for example, the method disclosed in CN1532196A can be referred to.
Specifically, R1Is cyclopentyl, R2Is methyl, R3Is phenyl, X is bromine; namely, the quinine compound containing the quaternary ammonium group shown in the formula (1) is benzcycloquine ammonium bromide (chemical name: 3- [ (2-cyclopentyl-2-hydroxy-2-phenyl) ethoxy]-1-methyl-bromo-1-azabicyclo [2,2]Octane, the specific structure is shown as the following formula:
the benzcycloquine bromide is an M-receptor blocker, and can be used for lowering blood pressure and treating angina pectoris.
According to the literature, benzenoquine ammonium bromide is synthesized mainly according to the following route:
experiments prove that the method has better refining effect on the benzcycloquine ammonium bromide.
In the above purification method, the ratio of the crude compound to the organic solvent-water mixed solution is not particularly limited, and it is preferable that the crude compound is sufficiently dissolved or a supersaturated solution is obtained. Further research shows that the proportion of the crude compound to the organic solvent-water mixed liquid is preferably 3g (3-30) ml, more preferably 3g (8-10) ml, and in the range, impurities in the product can be removed well, and the loss of the product in recrystallization can be reduced remarkably.
It was found that although there was no significant difference in the purity of the purified compound by using different organic solvents as described above, the difference was significant in the yield, which was much more than expected. Among them, when isopropanol is used, the refining effect is best, i.e. the yield is highest, and ethanol is used secondly.
Further, the volume ratio of the organic solvent to water in the organic solvent-water mixed solution is preferably (95:5) to (80:20), and more preferably 95: 5.
Researches show that when the solution containing the crude quinine compound containing the quaternary ammonium group is heated to the boiling point, especially heated to the temperature 3-7 ℃ higher than the boiling point, most of impurities such as inorganic salt, organic impurities and the like can be effectively removed, and the subsequent steps are facilitated to be rapidly crystallized, so that the purity is improved.
Generally, the purity of the crude quinine compound containing quaternary ammonium groups is more than or equal to 40 percent and usually between 60 and 80 percent, and the purity of the crude quinine compound refined by the method can reach more than 99.80 percent.
For purity, HPLC method can be used for determination, and CN101585835A can be specifically referred to.
The starting materials used in the present invention are commercially available or may be prepared by methods conventional in the art.
On the basis of the common knowledge in the field, the above preferred conditions can be combined with each other to obtain the preferred embodiments of the invention.
The method of the invention takes the organic solvent-water mixed solution as the refined solvent, reduces or avoids the use of organic solvent, reduces the pollution to the environment, avoids the use of organic solvent with higher toxicity such as acetone and the like, and is green and environment-friendly. The method reduces the refining times, simplifies the operation steps, reduces the cost, can prepare the high-purity quinine compound containing the quaternary ammonium group, and can effectively control the content of inorganic salt.
Detailed Description
The following examples are intended to illustrate the invention but are not intended to limit the scope of the invention. The examples do not show the specific techniques or conditions, according to the technical or conditions described in the literature in the field, or according to the product specifications. The reagents or instruments used are conventional products available from regular distributors, not indicated by the manufacturer.
The purity (HPLC) of the crude benzcycloquine ammonium bromide used below is 60.0%, and the benzcycloquine ammonium bromide can be prepared by the method in the reference CN 1257903C.
The following 95% aqueous isopropanol solution refers to a 95:5 ratio by volume of isopropanol to water.
Example 1
Adding 500ml of 95% isopropanol aqueous solution and 150g of benzoquinoline ammonium bromide crude product into a reaction bottle, refluxing to dissolve the solid, carrying out hot filtration, and cooling and crystallizing the filtrate. And (3) carrying out suction filtration and drying to constant weight to obtain white solid powder: 88.2g, yield: 98%, purity: 99.81% (HPLC), residue on ignition: 0.010%.
Example 2
400ml of 80% isopropanol aqueous solution and 120g of benzoquinoline ammonium bromide crude product are added into a reaction bottle, the mixture is refluxed to dissolve solids, the solid is filtered while the mixture is hot, and the filtrate is cooled and crystallized. And (3) carrying out suction filtration and drying to constant weight to obtain white solid powder: 68.4g, yield: 95%, purity: 99.80% (HPLC), residue on ignition: 0.013%.
Example 3
Adding 200ml of 95% ethanol aqueous solution and 60g of crude bencycloquine ammonium bromide into a reaction bottle, refluxing to dissolve the solid, filtering while the solution is hot, and cooling and crystallizing the filtrate. And (3) carrying out suction filtration, and drying to constant weight to obtain white solid powder: 32g, yield: 90%, purity: 99.89% (HPLC), residue on ignition: 0.010%.
Example 4
Adding 200ml of 80% ethanol solution and 60g of crude benzcycloquine ammonium bromide into a reaction bottle, refluxing to dissolve the solid, filtering while the solution is hot, and cooling and crystallizing the filtrate. And (3) carrying out suction filtration and drying to constant weight to obtain white solid powder: 32g, yield: 88%, purity: 99.85% (HPLC), residue on ignition: 0.011 percent.
Comparative example 1
130ml of distilled water and 50g of the crude benzcycloquine bromide are added into a reaction bottle, the mixture is refluxed to dissolve the solid, the solid is filtered while the mixture is hot, and the filtrate is cooled and crystallized. And (3) carrying out suction filtration and drying to constant weight to obtain white solid powder: 23.4g, yield: 78%, purity: 99.82% (HPLC), residue on ignition: 0.012 percent.
Furthermore, documents CN1532196A, CN1769286A, CN101585835A are incorporated herein in their entirety, as part hereof or as references herein.
Although the invention has been described in detail hereinabove with respect to a general description and specific embodiments thereof, it will be apparent to those skilled in the art that modifications or improvements may be made thereto based on the invention. Accordingly, such modifications and improvements are intended to be within the scope of the invention as claimed.
Claims (7)
1. A refining method of quinine compounds containing quaternary ammonium groups as shown in the following formula (1) is characterized by comprising the steps of mixing a crude product of the compound with an organic solvent-water mixed solution, heating to dissolve the crude product until the solution is clear, filtering while the solution is hot, and cooling and crystallizing filtrate; the organic solvent is isopropanol; the volume ratio of the organic solvent to the water in the organic solvent-water mixed solution is (95:5) - (80: 20); the proportion of the crude compound shown in the formula (1) to the organic solvent-water mixed solution is 3g (8-10) ml; the purity of the crude compound shown in the formula (1) is 60-80%;
(1)
R1independently selected from cyclopropyl, cyclopentyl or cyclohexyl;
R2independently selected from methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl or tert-butyl;
R3is phenyl;
x is independently selected from fluorine, chlorine, bromine, iodine.
2. The method according to claim 1, wherein the compound represented by formula (1) is benzcycloquine bromide.
3. The method according to claim 1 or 2, wherein the configuration of the compound of formula (1) is diastereomer or pure optical isomer.
4. The method according to claim 1 or 2, wherein the volume ratio of the organic solvent to water in the organic solvent-water mixture is 95: 5.
5. The process of claim 1 or 2, wherein the solution containing the crude quinine compound containing quaternary ammonium groups is heated to boiling point.
6. The process of claim 5, wherein the solution containing the crude quinine compound containing quaternary ammonium groups is heated to a temperature of 3-7 ℃ above the boiling point.
7. The method according to any one of claims 1, 2 and 6, wherein the purity of the crude compound represented by the formula (1) is 60%.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811615105.2A CN111377920B (en) | 2018-12-27 | 2018-12-27 | Method for refining quinine compound containing quaternary ammonium group |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811615105.2A CN111377920B (en) | 2018-12-27 | 2018-12-27 | Method for refining quinine compound containing quaternary ammonium group |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111377920A CN111377920A (en) | 2020-07-07 |
CN111377920B true CN111377920B (en) | 2021-10-26 |
Family
ID=71220762
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201811615105.2A Active CN111377920B (en) | 2018-12-27 | 2018-12-27 | Method for refining quinine compound containing quaternary ammonium group |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111377920B (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112684090A (en) * | 2021-03-22 | 2021-04-20 | 银谷制药有限责任公司 | Quality detection method of benzcycloquine bromide nasal spray |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1532196A (en) * | 2003-03-21 | 2004-09-29 | 北京小伙伴医药生物技术有限公司 | Quinic compound containing quaternary ammonium group and its preparation and medicina use |
CN1709891A (en) * | 2005-06-16 | 2005-12-21 | 成都力思特制药股份有限公司 | Medicinal compound, its composition and use in pharmaceutical process |
CN1769286A (en) * | 2005-10-20 | 2006-05-10 | 嘉事堂药业股份有限公司 | Compound and pharmaceutical composition for treating nasal oversecreation and chronic obstructive pulmonary disease |
CN1951938A (en) * | 2005-10-21 | 2007-04-25 | 刘丽娅 | Penehyclidine quaternary ammonium salt and its derivative |
CN101585835A (en) * | 2008-05-22 | 2009-11-25 | 北京嘉事联博医药科技有限公司 | Preparation method and application of bencycloquidium bromide optical isomer and composition of bencycloquidium bromide optical isomer |
CN102579356A (en) * | 2012-04-01 | 2012-07-18 | 成都力思特制药股份有限公司 | Preparation method of penehyclidine hydrochloride powder injection for injecting |
-
2018
- 2018-12-27 CN CN201811615105.2A patent/CN111377920B/en active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1532196A (en) * | 2003-03-21 | 2004-09-29 | 北京小伙伴医药生物技术有限公司 | Quinic compound containing quaternary ammonium group and its preparation and medicina use |
CN1709891A (en) * | 2005-06-16 | 2005-12-21 | 成都力思特制药股份有限公司 | Medicinal compound, its composition and use in pharmaceutical process |
CN1769286A (en) * | 2005-10-20 | 2006-05-10 | 嘉事堂药业股份有限公司 | Compound and pharmaceutical composition for treating nasal oversecreation and chronic obstructive pulmonary disease |
CN1951938A (en) * | 2005-10-21 | 2007-04-25 | 刘丽娅 | Penehyclidine quaternary ammonium salt and its derivative |
CN101585835A (en) * | 2008-05-22 | 2009-11-25 | 北京嘉事联博医药科技有限公司 | Preparation method and application of bencycloquidium bromide optical isomer and composition of bencycloquidium bromide optical isomer |
CN102579356A (en) * | 2012-04-01 | 2012-07-18 | 成都力思特制药股份有限公司 | Preparation method of penehyclidine hydrochloride powder injection for injecting |
Also Published As
Publication number | Publication date |
---|---|
CN111377920A (en) | 2020-07-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2014381760B2 (en) | Method for producing (R)-1,1,3-trimethyl-4-aminoindane | |
US2528267A (en) | Eobeet j | |
CN111630049B (en) | Process for preparing 2- (5-methoxyisochroman-1-yl) -4, 5-dihydro-1H-imidazole and bisulphates thereof | |
CN110845443B (en) | Method for preparing high-purity tolperisone hydrochloride | |
EP3424908A1 (en) | Process for preparation of levosimendan | |
CN111377920B (en) | Method for refining quinine compound containing quaternary ammonium group | |
WO2009139002A2 (en) | An improved process for the preparation of solifenacin and its pharmaceutically acceptable salts thereof | |
JP2001322979A (en) | Method for producing 3-bromoquinoline | |
CN106478657A (en) | The purification process of bisulfate clopidogrel | |
WO2007148191A2 (en) | An improved process for the preparation of aripiprazole | |
EP0127128B1 (en) | Process for the conversion of the e isomer of 1,2-diphenyl-1-(4-(2-dimethylaminoethoxy)-phenyl)-1-butene to tamoxifen hcl | |
US6545149B2 (en) | Synthesis and crystallization of piperazine ring-containing compounds | |
CN112645945B (en) | Preparation method of Wumei ammonium bromide intermediate | |
SU367602A1 (en) | ||
CN114539285A (en) | Preparation method of mabarosavir | |
CN111484445B (en) | Method for separating and purifying intermediate of high-purity Wumei ammonium bromide | |
JP2506376B2 (en) | Method for producing 2- (4-methylaminobutoxy) diphenylmethane hydrochloride | |
WO2003027106A1 (en) | Process for the preparation of crystalline polymorph ii of lamivudine | |
US20100010230A1 (en) | Method for the purification of lansoprazole | |
CN110015966B (en) | Preparation method of meclofenoxate hydrochloride | |
WO2023000135A1 (en) | Processes of making onapristone and intermediates thereof | |
EP2743263B1 (en) | An improved process for the preparation of levomepromazine maleate | |
CN103857679A (en) | Methods for the preparation of 5-[2-[7-(trifluoromethyl)-5-[4-(trifluoromethyl)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]ethynyl]-2-pyridinamine | |
CN102060752B (en) | Method for producing high-purity donepezil hydrochloride anhydrous I type crystal form and product thereof | |
US1750082A (en) | manchester |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |